April 12, 2022
The University of Cincinnati's Kyle Wang, MD, is the site principal investigator for the Trident trial, studying the effectiveness of earlier electrical treatment through Optune devices to treat glioblastomas.
February 7, 2023
The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.